Frontlight ResearchEarly access
CompletedPhase 1/2
pAF for the Treatment of Osteoarthritis
Key facts
- Who runs it
- University of Utah
- Where
- Salt Lake City, United StatesSee the site
- Trial code
- Status
- Completed
- Phase
- Phase 1/2
- People taking part
- 60 people enrolled
- Started
- 8 Jul 2021
- Ended
- 31 Jan 2025
- Type of study
- Interventional, 2 groupsOne group gets an existing treatment, for comparison.
- Treatments tested
- Amniotic Fluid Injection
- Standard of Care
- Record updated
- 27 March 2026
Who can take part
- Age
- 18 years to 70 years
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
Show the full registry criteria (25)Hide the full registry criteria
Who can take part
- Patients who are between the ages of 18-70 years
- A confirmed diagnosis of knee osteoarthritis based on clinical and radiographic findings consistent with Kellgren-Lawrence Stage 2-3 disease
- Patients who have failed conservative treatment (e.g. steroid, activity modification, therapy, etc.) within 3 months
- Unilateral or bilateral chronic knee joint pain >4 months
- Patients who are able to ambulate (i.e. not wheelchair bound)
- Patient reported a typical pain of at least 4 out of 10 during the past week using VAS numeric pain scale (0-10)
- Patients who are of childbearing potential must agree to use adequate contraception for 90 days after study drug injection
Who cannot take part
- Concurrent participation in another investigational trial involving systemic administration of agents (within the previous 30 days) or plans to participate in any other allogeneic stem cell therapy trial during the 12 month follow-up period
- Any surgeries within 4 weeks, other than diagnostic surgery
- Patients with known alcohol or drug abuse or dependence, recreational use of illicit drug or prescription medications, or have used medical marijuana within 7 days of study enrollment
- Patients of childbearing potential who are unwilling to use adequate contraception for 90 days after study drug injection
- Clinical suspicion of infection at injection site
- Patients with a known allergy to local anesthetics or components of the study drug (pAF or steroid injection)
- Patients with vascular claudication or neurologic disorders affecting the index lower limb
- Patients with inflammatory arthropathies or connective tissue disorders; or
- Patients with history of active cancer/malignancy within 2 years of screening, apart from adequately treated basal cell or squamous cell carcinoma of the skin not associated with the target knee
- Subjects who have had a previous injection (i.e. steroid, platelet rich plasma, or other) within the last 3 months
- A focal chondral defect, defined by x-ray evaluation
- BMI >40 as defined by NIH Clinical Guidelines Body Mass Index
- Insulin or self-reported non-insulin dependent diabetic evident of HgA1c ≥8% among known diabetics
- Unable to consent to an English Language Consent Form
- Frank mechanical issues (i.e. locking of the knee)
- Workman's Compensation cases
- Rheumatoid arthritis
- Women who are nursing or pregnant
Where in United States
- University of Utah Orthopedic CenterSalt Lake City, United States
About the trial
What the trial wants to find out
This is a Phase I/II Randomized Double-Blinded Standard of Care (Corticosteroid) vs. Sterile Amniotic Fluid for Osteoarthritis
The 2 groups in the trial
- Amniotic Fluid InjectionTreatment being tested
Amniotic Fluid Injection, 3ml, one time dose.
- Standard of Care Steroid InjectionExisting treatment, for comparison
Corticosteroids, 3ml, one time dose.
Treatment: Standard of Care
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- A Phase I/II Randomized Double-Blinded Standard of Care (Corticosteroid) vs. Sterile Amniotic Fluid for Osteoarthritis
- Record updated
- 27 March 2026